Emerging Trends Influencing The Growth Of The Pulmonary Embolism Market: Leading Companies In The Pulmonary Embolism Market Innovate With Advanced Catheter Solutions

The Pulmonary Embolism Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Pulmonary Embolism Market Size Expected to Be by 2034?
Over the past few years, the market size for pulmonary embolism has seen a significant expansion. It is projected to increase from $2.03 billion in 2024 to $2.27 billion in 2025, growing at a compound annual growth rate (CAGR) of 11.9%. The historical period's growth can be traced back to factors such as anticoagulant therapies, research and clinical trials, heightened awareness of pulmonary embolism, and VTE prophylaxis.

In the upcoming years, the market size of pulmonary embolism is predicted to encounter swift escalation. The market value is expected to rise to $3.63 billion by 2029, progressing at a Compound Annual Growth Rate (CAGR) of 12.5%. Factors contributing to the projected growth during this period include targeted therapies, telemedicine and remote patient monitoring, health equity programs and global health campaigns. The anticipated trends in the said period encompass the application of artificial intelligence in diagnosis, the introduction of novel anticoagulants, the establishment of pulmonary embolism response teams, and an increased focus on patient-centric care.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026

What Are the Emerging Segments Within the Pulmonary Embolism Market?
The pulmonary embolism market covered in this report is segmented -

1) By Treatment: Medications, Mechanical Devices, Other Treatments
2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis
3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Medications: Anticoagulants, Thrombolytics
2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy
3) By Other Treatments: Surgical Embolectomy, Supportive Care

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

What Long-Term Drivers Are Shaping Pulmonary Embolism Market Trends?
The rising incidence of blood clots is anticipated to boost the pulmonary embolism market's expansion. A blood clot, often referred to as a thrombus, is a semi-solid or gel-like mass that takes shape within a blood vessel. As they block the passage of blood to the lungs, these clots elevate the risk of pulmonary embolism. A typical cause is the blockage of deep veins in the legs, escalating the threat of pulmonary embolism. For example, Gavi, the Vaccine Alliance, an international body aimed at enhancing child access to new and underused vaccines, reported in April 2022 that research revealed a 33-fold surge in potentially lethal lung clot possibilities and a five-fold heightening in deep vein thrombosis risk in the 30 days post-COVID 19 exposure. Consequently, the escalating incidence of blood clots is fostering the pulmonary embolism market's growth. The pulmonary embolism market's growth is expected to be fueled by the surge in cancer prevalence. Cancer constitutes several diseases, identified by the uncontrolled and abnormal proliferation of body cells. The rise in cancer cases increases the likelihood of blood clots, like pulmonary embolism, in those afflicted, elevating the requirement for diagnosis and treatments, inclusive of particular drugs. The American Cancer Society, a US-based non-profit committed to cancer advocacy, stated in January 2024 that cancer cases rose to 2,001,140 from 1,958,310 in 2023, marking a 2.19% increase. Thus, the rising incidence of cancer contributes to the expansion of the pulmonary embolism market.

Who Are the Top Competitors in Key Pulmonary Embolism Market Segments?
Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

What Pulmonary Embolism Market Trends Are Gaining Traction Across Different Segments?
Leading businesses in the pulmonary embolism market are targeting the creation of novel products like the Triever16 Curve catheter and the RevCore thrombectomy catheter to gain a competitive edge. For example, Inari Medical Inc., an American medical device firm, unveiled the Triever16 Curve catheter and the RevCore thrombectomy catheter in June 2023. The innovative Triever16 Curve catheter, tailor-made for peripheral thrombectomy and pulmonary embolism operations, boasts superior trackability and a pre-moulded curve for targeted aspiration. The catheter also showcases a special design that facilitates simple access to larger, more potent 20F or 24F catheters, while the RevCore thrombectomy catheter is purpose-built to handle venous in-stent thrombosis. Functioning as a mechanical thrombectomy apparatus, it employs a nitinol basket for trapping and eliminating blood clots. These catheters also contribute to enhancing the safety and efficacy of pulmonary embolism procedures.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Which Regions Are Becoming Hubs for Pulmonary Embolism Market Innovation?
North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Pulmonary Embolism Market?
2. What is the CAGR expected in the Pulmonary Embolism Market?
3. What Are the Key Innovations Transforming the Pulmonary Embolism Industry?
4. Which Region Is Leading the Pulmonary Embolism Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.